Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Phase 2 Completed 107 enrolled ViiV Healthcare GlaxoSmithKline · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to study the safety and tolerability of a HIV drug and to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected patients

Timeline

Start: 2013-04-04
Primary completion: 2014-11-29
Completion: 2014-11-29

Publications

Hwang C, Schurmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, Ravindran P, Xiao H, Keicher C, Huser A, Krystal M, Dicker IB, Grasela D, Lataillade M. Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002). Clin Infect Dis. 2017 Aug 1;65(3):442-452. doi: 10.1093/cid/cix239.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-955176	Other / unclassified	5 mg	Oral
Subject	BMS-955176	Other / unclassified	10 mg	Oral
Subject	BMS-955176	Other / unclassified	20 mg	Oral
Subject	BMS-955176	Other / unclassified	40 mg	Oral
Subject	BMS-955176	Other / unclassified	80 mg	Oral
Subject	BMS-955176	Other / unclassified	120 mg	Oral
Background	Atazanavir	Other / unclassified	300 mg	Oral
Background	Atazanavir	Other / unclassified	400 mg	Oral
Background	Ritonavir	Other / unclassified	100 mg	Oral
Background	Tenofovir	Small molecule	300 mg	Oral
Background	emtricitabine	Other / unclassified	200 mg	—

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Summary

Timeline

Publications

Drugs

Indications